The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Summary: Hypothalamic obesity does not respond well to conventional interventions for obesity. GLP‐1 receptor agonists have mechanisms independent of the hypothalamus which may be potentially beneficial for managing hypothalamic obesity. This systematic review summarizes the efficacy and safety of GLP‐1 receptor agonists use in hypothalamic obesity. A PRISMA‐compliant systematic review was performed. Data was extracted from included studies and analysed based on change in weight, body mass index, glycaemic control, satiety, and safety profile with GLP‐1 receptor agonist use. Ten studies comprising 5 case reports, 4 case series and 1 randomized‐controlled trial included 54 patients (24 males, 30 females) with mean age of 25.2 (range 13–71) years with hypothalamic obesity who had received GLP‐1 receptor agonists (exenatide = 48, liraglutide = 5 and dulaglutide = 1) over a mean duration of treatment of 12 (range 3–51) months. Mean weight reduction of 7.4 (SD 7.92) kg was observed in patients in whom weight was reported, with 85.7% of patients experiencing weight loss. All patients on liraglutide had weight reduction post‐therapy. The sole trial had reported a non‐significant reduction in BMI post‐exenatide. Glycaemic control had either improved/maintained in all patients in whom this was measured. The main side effects of GLP‐1 receptor agonist in individuals with hypothalamic obesity were nausea and vomiting; there were no major safety concerns. Based on limited published experience, GLP‐1RA may be effective and safe for weight control in hypothalamic obesity, with the added benefit of improved glycaemic control in those with concurrent diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent systematic review on glucagon-like peptide (GLP) receptor-1 treatment for hypothalamic obesity, in which 10 studies were included, reported that treatment with GLP-1 analogues may be effective and safe for weight control in hypothalamic obesity (120).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chapter 7: Systematic reviews of etiology and risk
Moola, S., Munn, Z., Tufanaru, C., Aromataris, E., Sears, K., Sfetic, R., Currie, M., Lisy, K., Qureshi, R., Mattis, P., et al. (2019) · JBI Reviewer's Manual · doi:10.46658/jbirm-17-06 · Cited by 2,114
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723 · cited 1×
“10,11 GLP-1 is a gut incretin secreted from intestinal neuroendocrine L-cells in response to food intake.”
BackgroundCraniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up
Karavitaki, N., Brufani, C., Warner, J. T., Adams, C. B. T., Richards, P., Ansorge, O., Shine, B., Turner, H. E., & Wass, J. A. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02231.x · Cited by 633
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · cited 1×
“34,35 Indeed, endogenous GLP-1 has been shown to exert appetite-suppressing effects through GLP-1 receptors on vagal afferent fibres, which has direct actions on gastric emptying and satiety.”
BackgroundMüller, H. L., Gebhardt, U., Teske, C., Faldum, A., Zwiener, I., Warmuth-Metz, M., Pietsch, T., Pohl, F., Sörensen, N., & Calaminus, G. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0158 · Cited by 302
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269 · cited 1×
“18,36,37 In addition, circulating GLP-1 acts on GLP-1 receptors in areas of the hindbrain beyond the hypothalamus that are involved in appetite homeostasis.”
BackgroundWeight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31982 · Cited by 238 · cited 1×
“14,15 In theory, the central and peripheral actions of GLP1-RA make it a potential therapeutic strategy for treatment of HO.”
BackgroundPannacciulli, N., Le, D. S. N. T., Salbe, A. D., Chen, K., Reiman, E. M., Tataranni, P. A., & Krakoff, J. A. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.035 · Cited by 182
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases
Zoicas, F., Droste, M., Mayr, B., Buchfelder, M., & Schöfl, C. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0997 · Cited by 122
Hypothalamic obesity in children
Bereket, A., Kiess, W., Lustig, R. H., Muller, H. L., Goldstone, A. P., Weiss, R., Yavuz, Y., & Hochberg, Z. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01004.x · Cited by 119
Muller, H. L. (2012) · Pituitary · doi:10.1007/s11102-012-0401-0 · Cited by 111
Heymsfield, S. B., Avena, N. M., Baier, L., Brantley, P., Bray, G. A., Burnett, L. C., Butler, M. G., Driscoll, D. J., Egli, D., Elmquist, J., et al. (2014) · Obesity · doi:10.1002/oby.20646 · Cited by 90
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
Müller, H. L., Gebhardt, U., Etavard-Gorris, N., Korenke, E., Warmuth-Metz, M., Kolb, R., Sörensen, N., & Calaminus, G. (2004) · Klinische Pädiatrie · doi:10.1055/s-2004-832339 · Cited by 85
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Late mortality in pediatric patients with craniopharyngioma
Visser, J., Hukin, J., Sargent, M. A., Steinbok, P., Goddard, K., & Fryer, C. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0145-5 · Cited by 71
Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans
Lee, M., & Körner, J. (2008) · Pituitary · doi:10.1007/s11102-008-0096-4 · Cited by 63
Hoffmann, A., Postma, F. P., Sterkenburg, A. S., Gebhardt, U., & Müller, H. L. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0415 · Cited by 59
Lomenick, J. P., Buchowski, M. S., & Shoemaker, A. H. (2016) · Obesity · doi:10.1002/oby.21493 · Cited by 58
Ng, N. B. H., Low, Y. W., Rajgor, D. D., Low, J. M., Lim, Y. Y., Loke, K. Y., & Lee, Y. S. (2021) · Clinical Endocrinology · doi:10.1111/cen.14583 · Cited by 53
Self-citationRakhshani, N., Jeffery, A. S., Schulte, F., Barrera, M., Atenafu, E. G., & Hamilton, J. K. (2010) · Obesity · doi:10.1038/oby.2009.491 · Cited by 43
Craniopharyngioma in Children: Long-term Outcomes
STEINBOK, P. (2015) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2015-0099 · Cited by 43
Shoemaker, A. H., Silver, H. J., Buchowski, M., Slaughter, J. C., Yanovski, J. A., Elfers, C., Roth, C. L., & Abuzzahab, M. J. (2022) · International Journal of Obesity · doi:10.1038/s41366-021-01043-6 · Cited by 38
Thondam, S. K., Cuthbertson, D. J., Aditya, B. S., MacFarlane, I. A., Wilding, J. P. H., & Daousi, C. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04368.x · Cited by 33
Ando, T., Haraguchi, A., Matsunaga, T., Natsuda, S., Yamasaki, H., Usa, T., & Kawakami, A. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1646 · Cited by 31
Perez, F. A., Elfers, C., Yanovski, J. A., Shoemaker, A. H., Abuzzahab, M. J., & Roth, C. L. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14366 · Cited by 29 · cited 2×
“29 The other clinical trial on exenatide (CRANIOEXE, NCT02860923) had been completed more than 5 years ago.”
BackgroundSimmons, J. H., Shoemaker, A. H., & Roth, C. L. (2012) · Hormone Research in Paediatrics · doi:10.1159/000339469 · Cited by 29
van Schaik, J., Begijn, D. G. A., van Iersel, L., Vergeer, Y., Hoving, E. W., Peeters, B., & van Santen, H. M. (2020) · Obesity Facts · doi:10.1159/000509302 · Cited by 25
Bretault, M., Carette, C., Zaharia, R., Vychnevskaia, K., Bouillot, J.-L., Czernichow, S., & Raffin-Sanson, M.-L. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.07.004 · Cited by 20 · cited 1×
“25 Indeed, a study found that patients with craniopharyngioma had a loss of post-prandial GLP-1 secretion which was restored after gastric-bypass surgery, where restoration of GLP-1 secretion correlated with weight loss and reduced appetite.”
BackgroundNi, W., & Shi, X. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.06.121 · Cited by 18
Castro-Dufourny, I., Carrasco, R., & Pascual, J. M. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2016.10.006 · Cited by 17
Bretault, M., Laroche, S., Lacorte, J., Barsamian, C., Polak, M., Raffin‐Sanson, M., Touraine, P. A., Bouillot, J., Czernichow, S., & Carette, C. (2016) · Obesity Surgery · doi:10.1007/s11695-015-1977-z · Cited by 15
Liraglutide for the Treatment of Hypothalamic Obesity
Ashraf, S., Nadkarni, P., Bansal, N., & Stred, S. E. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0009 · Cited by 4
Gatta‐Cherifi, B., Mohammedi, K., Cariou, T., Poitou, C., Touraine, P. A., Raverot, G., Brue, T. C., Chanson, P., Illouz, F., Solange, G., et al. (2023) · Endocrine Abstracts · doi:10.1530/endoabs.90.p369
Research works printed but not linked: 3
- Higgins JPT, 2021, Cochrane Handbook for Systematic Reviews of Interventions
- Moola S, 2017, Joanna Briggs Institute Reviewer's Manual
- Sultana R, 2022, The case for early use of glucagon‐like Peptide‐1 receptor agonists in obstructive sleep apnea patients with comorbid diabetes and metabolic syndrome, Life (Basel), 12, 12
Cited by
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
(2025) · Advances in Cancer Research · doi:10.1016/bs.acr.2025.09.005 · Cited by 5
Metadata
- Authors
- Ng, V. W. W., Gerard, G., Koh, J. J. K., Loke, K. Y., Lee, Y. S., & Ng, N. B. H.
- Affiliations
- Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
- Khoo Teck Puat – National University Children's Medical Institute, Department of Paediatrics National University Hospital Singapore Singapore
- Venue
- Clinical Obesity
- Publisher
- Wiley
- Published
- 2024-01-25
- Volume
- 14
- Issue
- 3
- ISSN
- 1758-8103
- 1758-8111
- Cited by
- 21
- References
- 37
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.